B-type Natriuretic Peptide circulating forms: Analytical and bioactivity issues

Clinica Chimica Acta

Volumn 448, Issue , 2015, Pages 195-205

  Yandle, Tim G ^a   Richards, A Mark ^a,b  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b NATIONAL UNIVERSITY HEALTH SYSTEM   (Singapore)

Author keywords

BNP; Glycosylation; Natriuretic peptide; NT proBNP; ProBNP; Truncation

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BRAIN NATRIURETIC PEPTIDE; CARBOXY TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; DIPEPTIDYL PEPTIDASE IV; INSULINASE; MEMBRANE METALLOENDOPEPTIDASE; MEPRIN; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; AMINO TERMINAL SEQUENCE; CARBOXY TERMINAL SEQUENCE; CROSS REACTION; HUMAN; IMMUNOREACTIVITY; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN GLYCOSYLATION; PROTEIN PROCESSING; PROTEIN SECRETION; PROTEIN SYNTHESIS; REVIEW; GLYCOSYLATION; IMMUNOASSAY; METABOLISM;

GLYCOSYLATION; HUMANS; IMMUNOASSAY; NATRIURETIC PEPTIDE, BRAIN;

EID: 84937238986     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2015.07.004     Document Type: Review

References (98)

1. Yasue H., Yoshimura M., Sumida H., et al. Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation 1994, 90:195-203.
2. LaPointe M.C. Molecular regulation of the brain natriuretic peptide gene. Peptides 2005, 26:944-956.
3. Potter L.R. Guanylyl cyclase structure, function and regulation. Cell. Signal. 2011, 23:1921-1926.
4. Potter L.R. Natriuretic peptide metabolism, clearance and degradation. FEBS J. 2011, 278:1808-1817.
5. Charles C.J., Espiner E.A., Nicholls M.G., et al. Clearance receptors and endopeptidase 24.11: equal role in natriuretic peptide metabolism in conscious sheep. Am. J. Physiol. 1996, 271:R373-R380.
6. Lainchbury J.G., Richards A.M., Nicholls M.G., Espiner E.A., Yandle T.G. Brain natriuretic peptide and neutral endopeptidase inhibition in left ventricular impairment. J. Clin. Endocrinol. Metab. 1999, 84:723-729.
7. Boerrigter G., Costello-Boerrigter L.C., Burnett J.C. Natriuretic peptides in the diagnosis and management of chronic heart failure. Heart Fail. Clin. 2009, 5:501-514.
8. Espiner E.A. Physiology of natriuretic peptides. J. Intern. Med. 1994, 235:527-541.
9. Holmes S.J., Espiner E.A., Richards A.M., Yandle T.G., Frampton C. Renal, endocrine, and hemodynamic effects of human brain natriuretic peptide in normal man. J. Clin. Endocrinol. Metab. 1993, 76:91-96.
10. Cataliotti A., Chen H.H., Redfield M.M., Burnett J.C. Natriuretic peptides as regulators of myocardial structure and function: pathophysiologic and therapeutic implications. Heart Fail. Clin. 2006, 2:269-276.
11. Calvieri C., Rubattu S., Volpe M. Molecular mechanisms underlying cardiac antihypertrophic and antifibrotic effects of natriuretic peptides. J. Mol. Med. 2012, 90:5-13.
12. Hunt P.J., Richards A.M., Nicholls M.G., Yandle T.G., Doughty R.N., Espiner E.A. Immunoreactive amino-terminal pro-brain natriuretic peptide (NT-PROBNP): a new marker of cardiac impairment. Clin. Endocrinol. 1997, 47:287-296.
13. Davis M., Espiner E., Richards G., et al. Plasma brain natriuretic peptide in assessment of acute dyspnoea. Lancet 1994, 343:440-444.
14. Maisel A.S., Krishnaswamy P., Nowak R.M., et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N. Engl. J. Med. 2002, 347:161-167.
15. Maisel A.S., Daniels L.B. Breathing not properly 10years later: what we have learned and what we still need to learn. J. Am. Coll. Cardiol. 2012, 60:277-282.
16. Januzzi J.L., van Kimmenade R., Lainchbury J., et al. NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients: the International Collaborative of NT-proBNP Study. Eur. Heart J. 2006, 27:330-337.
17. Yancy C.W., Jessup M., Bozkurt B., et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 2013, 128:e240-e327.
18. Hino J., Tateyama H., Minamino N., Kangawa K., Matsuo H. Isolation and identification of human brain natriuretic peptides in cardiac atrium. Biochem. Biophys. Res. Commun. 1990, 167:693-700.
19. Tateyama H., Hino J., Minamino N., Kangawa K., Ogihara T., Matsuo H. Characterization of immunoreactive brain natriuretic peptide in human cardiac atrium. Biochem. Biophys. Res. Commun. 1990, 166:1080-1087.
20. Sudoh T., Maekawa K., Kojima M., Minamino N., Kangawa K., Matsuo H. Cloning and sequence analysis of cDNA encoding a precursor for human brain natriuretic peptide. Biochem. Biophys. Res. Commun. 1989, 159:1427-1434.
21. Mukoyama M., Nakao K., Hosoda K., et al. Brain natriuretic peptide as a novel cardiac hormone in humans - evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide. J. Clin. Invest. 1991, 87:1402-1412.
22. Tateyama H., Hino J., Minamino N., et al. Concentrations and molecular forms of human brain natriuretic peptide in plasma. Biochem. Biophys. Res. Commun. 1992, 185:760-767.
23. Yandle T.G., Richards A.M., Gilbert A., Fisher S., Holmes S., Espiner E.A. Assay of brain natriuretic peptide (BNP) in human plasma: evidence for high molecular weight BNP as a major plasma component in heart failure. J. Clin. Endocrinol. Metab. 1993, 76:832-838.
24. Hunt P.J., Yandle T.G., Nicholls M.G., Richards A.M., Espiner E.A. The amino-terminal portion of pro-brain natriuretic peptide (Pro-BNP) circulates in human plasma. Biochem. Biophys. Res. Commun. 1995, 214:1175-1183.
25. Semenov A.G., Tamm N.N., Seferian K.R., et al. Processing of pro-B-type natriuretic peptide: furin and corin as candidate convertases. Clin. Chem. 2010, 56:1166-1176.
26. Costello-Boerrigter L.C., Lapp H., Boerrigter G., et al. Secretion of prohormone of B-type natriuretic peptide, proBNP1-108, is increased in heart failure. JACC Heart Fail. 2013, 1:207-212.
27. Stephenson S.L., Kenny A.J. The hydrolysis of a-human atrial natriuretic peptide by pig kidney microvillar membranes is initiated by endopeptidase-24.11. Biochem. J. 1987, 243:183-187.
28. Vanneste Y., Michel A., Dimaline R., Najdovski T., Deschodt-Lanckman M. Hydrolysis of alpha-human atrial natriuretic peptide in vitro by human kidney membranes and purified endopeptidase-24.11. Evidence for a novel cleavage site. Biochem. J. 1988, 254:531-537.
29. Kenny A.J., Stephenson S.L. Role of endopeptidase-24.11 in the inactivation of atrial natriuretic peptide. FEBS Lett. 1988, 232:1-8.
30. Seymour A.A., Swerdel J.N., Fennell S.A., Delaney N.G. Atrial natriuretic peptides cleaved by endopeptidase are inactive in conscious spontaneously hypertensive rats. Life Sci. 1988, 43:2265-2274.
31. Charles C.J., Espiner E.A., Yandle T.G., Cameron V.A., Richards A.M. Biological actions of cleaved atrial natriuretic factor (ANF101-105/106-126) in conscious sheep. J. Cardiovasc. Pharmacol. 1991, 17:403-410.
32. Yandle T., Crozier I., Nicholls G., Espiner E., Carne A., Brennan S. Amino acid sequence of atrial natriuretic peptides in human coronary sinus plasma. Biochem. Biophys. Res. Commun. 1987, 146:832-839.
33. Norman J.A., Little D., Bolgar M., Di Donato G. Degradation of brain natriuretic peptide by neutral endopeptidase: species specific sites of proteolysis determined by mass spectrometry. Biochem. Biophys. Res. Commun. 1991, 175:22-30.
34. Kenny A.J., Bourne A., Ingram J. Hydrolysis of human and pig brain natriuretic peptides, urodilatin, C-type natriuretic peptide and some C-receptor ligands by endopeptidase-24.11. Biochem. J. 1993, 291:83-88.
35. Watanabe Y., Nakajima K., Shimamori Y., Fujimoto Y. Comparison of the hydrolysis of the three types of natriuretic peptides by human kidney neutral endopeptidase 24.11. Biochem. Mol. Med. 1997, 61:47-51.
36. Brandt I., Lambeir A.M., Ketelslegers J.M., Vanderheyden M., Scharpe S., De Meester I. Dipeptidyl-peptidase IV converts intact B-type natriuretic peptide into its des-SerPro form. Clin. Chem. 2006, 52:82-87.
37. Walther T., Stepan H., Pankow K., Becker M., Schultheiss H.P., Siems W.E. Biochemical analysis of neutral endopeptidase activity reveals independent catabolism of atrial and brain natriuretic peptide. Biol. Chem. 2004, 385:179-184.
38. Smith M.W., Espiner E.A., Yandle T.G., Charles C.J., Richards A.M. Delayed metabolism of human brain natriuretic peptide reflects resistance to neutral endopeptidase. J. Endocrinol. 2000, 167:239-246.
39. Lambeir A.M., Durinx C., Scharpe S., De Meester I. Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV. Crit. Rev. Clin. Lab. Sci. 2003, 40:209-294.
40. Vanderheyden M., Bartunek J., Goethals M., et al. Dipeptidyl-peptidase IV and B-type natriuretic peptide. From bench to bedside. Clin. Chem. Lab. Med. 2009, 47:248-252.
41. Deacon C.F. Circulation and degradation of GIP and GLP-1. Horm. Metab. Res. 2004, 36:761-765.
42. Deacon C.F., Carr R.D., Holst J.J. DPP-4 inhibitor therapy: new directions in the treatment of type 2 diabetes. Front. Biosci. 2008, 13:1780-1794.
43. Lam C.S., Burnett J.C., Costello-Boerrigter L., Rodeheffer R.J., Redfield M.M. Alternate circulating pro-B-type natriuretic peptide and B-type natriuretic peptide forms in the general population. J. Am. Coll. Cardiol. 2007, 49:1193-1202.
44. Fernandez-Gamba A., Leal M.C., Morelli L., Castano E.M. Insulin-degrading enzyme: structure-function relationship and its possible roles in health and disease. Curr. Pharm. Des. 2009, 15:3644-3655.
45. Ralat L.A., Guo Q., Ren M., et al. Insulin-degrading enzyme modulates the natriuretic peptide-mediated signaling response. J. Biol. Chem. 2011, 286:4670-4679.
46. Pankow K., Wang Y., Gembardt F., et al. Successive action of meprin A and neprilysin catabolizes B-type natriuretic peptide. Circ. Res. 2007, 101:875-882.
47. Walther T. Screening Methods for Inhibitors of the Metalloprotease Meprin 2007, World International Property Organisation, (Publication Number WO/2007/003594).
48. Dickey D.M., Potter L.R. Human B-type natriuretic peptide is not degraded by meprin A. Biochem. Pharmacol. 2010, 80:1007-1011.
49. Shimizu H., Masuta K., Aono K., et al. Molecular forms of human brain natriuretic peptide in plasma. Clin. Chim. Acta 2002, 316:129-135.
50. Hawkridge A.M., Heublein D.M., Bergen H.R., Cataliotti A., Burnett J.C., Muddiman D.C. Quantitative mass spectral evidence for the absence of circulating brain natriuretic peptide (BNP-32) in severe human heart failure. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:17442-17447.
51. Niederkofler E.E., Kiernan U.A., O'Rear J., et al. Detection of endogenous B-type natriuretic peptide at very low concentrations in patients with heart failure. Circ. Heart Fail. 2008, 1:258-264.
52. Miller W.L., Phelps M.A., Wood C.M., et al. Comparison of mass spectrometry and clinical assay measurements of circulating fragments of B-type natriuretic peptide in patients with chronic heart failure. Circ. Heart Fail. 2011, 4:355-360.
53. Fujimoto H., Suzuki T., Aizawa K., et al. Processed B-type natriuretic peptide is a biomarker of postinterventional restenosis in ischemic heart disease. Clin. Chem. 2013, 59:1330-1337.
54. Heublein D.M., Huntley B.K., Boerrigter G., et al. Immunoreactivity and guanosine 3',5'-cyclic monophosphate activating actions of various molecular forms of human B-type natriuretic peptide. Hypertension 2007, 49:1114-1119.
55. Rawlins M.L., Owen W.E., Roberts W.L. Performance characteristics of four automated natriuretic peptide assays. Am. J. Clin. Pathol. 2005, 123:439-445.
56. Tetin S.Y., Ruan Q., Saldana S.C., et al. Interactions of two monoclonal antibodies with BNP: high resolution epitope mapping using fluorescence correlation spectroscopy. Biochemistry 2006, 45:14155-14165.
57. A table of BNP and NTproBNP diagnostic assays and antibodies used in them is available on the International Federation of Clinical Chemistry website http://www.ifcc.org/ifcc-scientific-division/documents-of-the-sd/.
58. Luckenbill K.N., Christenson R.H., Jaffe A.S., et al. Cross-reactivity of BNP, NT-proBNP, and proBNP in commercial BNP and NT-proBNP assays: preliminary observations from the IFCC Committee for Standardization of Markers of Cardiac Damage. Clin. Chem. 2008, 54:619-621.
59. Liang F., O'Rear J., Schellenberger U., et al. Evidence for functional heterogeneity of circulating B-type natriuretic peptide. J. Am. Coll. Cardiol. 2007, 49:1071-1078.
60. Nishikimi T., Minamino N., Horii K., Matsuoka H. Do commercially available assay kits for B-type natriuretic peptide measure pro-BNP1-108, as well as BNP1-32?. Hypertension 2007, 50:e163. (author reply e164).
61. Roubille F., Delseny D., Cristol J.P., et al. Depletion of proBNP1-108 in patients with heart failure prevents cross-reactivity with natriuretic peptides. PLoS One 2013, 8:e75174.
62. Vodovar N., Seronde M.F., Laribi S., et al. Post-translational modifications enhance NT-proBNP and BNP production in acute decompensated heart failure. Eur. Heart J. 2014, 35:3434-3441.
63. Boerrigter G., Costello-Boerrigter L.C., Harty G.J., et al. B-type natriuretic peptide 8-32, which is produced from mature BNP 1-32 by the metalloprotease meprin A, has reduced bioactivity. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2009, 296:R1744-R1750.
64. Boerrigter G., Costello-Boerrigter L.C., Harty G.J., Lapp H., Burnett J.C. Des-serine-proline brain natriuretic peptide 3-32 in cardiorenal regulation. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2007, 292:R897-R901.
65. Mahagamasekera P.G., Ruygrok P.N., Palmer S.C., et al. B-type natriuretic peptide forms within the heart, coronary sinus, and peripheral circulation in humans: evidence for degradation before secretion. Clin. Chem. 2014, 60:549-558.
66. Kuo W.L., Montag A.G., Rosner M.R. Insulin-degrading enzyme is differentially expressed and developmentally regulated in various rat tissues. Endocrinology 1993, 132:604-611.
67. Linardi A., Panunto P.C., Ferro E.S., Hyslop S. Peptidase activities in rats treated chronically with N(omega)-nitro-l-arginine methyl ester (l-NAME). Biochem. Pharmacol. 2004, 68:205-214.
68. Fielitz J., Dendorfer A., Pregla R., et al. Neutral endopeptidase is activated in cardiomyocytes in human aortic valve stenosis and heart failure. Circulation 2002, 105:286-289.
69. Kokkonen J.O., Kuoppala A., Saarinen J., Lindstedt K.A., Kovanen P.T. Kallidin- and bradykinin-degrading pathways in human heart: degradation of kallidin by aminopeptidase M-like activity and bradykinin by neutral endopeptidase. Circulation 1999, 99:1984-1990.
70. Raizada V., Luo W., Skipper B.J., McGuire P.G. Intracardiac expression of neutral endopeptidase. Mol. Cell. Biochem. 2002, 232:129-131.
71. Hartel S., Gossrau R., Hanski C., Reutter W. Dipeptidyl peptidase (DPP) IV in rat organs. Comparison of immunohistochemistry and activity histochemistry. Histochemistry 1988, 89:151-161.
72. Matheeussen V., Baerts L., De Meyer G., et al. Expression and spatial heterogeneity of dipeptidyl peptidases in endothelial cells of conduct vessels and capillaries. Biol. Chem. 2011, 392:189-198.
73. Hansen L., Deacon C.F., Orskov C., Holst J.J. Glucagon-like peptide-1-(7-36)amide is transformed to glucagon-like peptide-1-(9-36)amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine. Endocrinology 1999, 140:5356-5363.
74. Shimizu H., Masuta K., Asada H., Sugita K., Sairenji T. Characterization of molecular forms of probrain natriuretic peptide in human plasma. Clin. Chim. Acta 2003, 334:233-239.
75. Giuliani I., Rieunier F., Larue C., et al. Assay for measurement of intact B-type natriuretic peptide prohormone in blood. Clin. Chem. 2006, 52:1054-1061.
76. Hammerer-Lercher A., Halfinger B., Sarg B., et al. Analysis of circulating forms of proBNP and NT-proBNP in patients with severe heart failure. Clin. Chem. 2008, 54:858-865.
77. Dries D.L., Ky B., Wu A.H., Rame J.E., Putt M.E., Cappola T.P. Simultaneous assessment of unprocessed ProBNP1-108 in addition to processed BNP32 improves identification of high-risk ambulatory patients with heart failure. Circ. Heart Fail. 2010, 3:220-227.
78. Macheret F., Boerrigter G., McKie P., et al. Pro-B-type natriuretic peptide(1-108) circulates in the general community: plasma determinants and detection of left ventricular dysfunction. J. Am. Coll. Cardiol. 2011, 57:1386-1395.
79. Miller W.L., Grill D.E., Jaffe A.S. Comparison of novel pro-BNP(1-108) and standard BNP assays in heart failure patients. Clin. Chim. Acta 2012, 413:920-926.
80. Ala-Kopsala M., Moilanen A.M., Rysa J., Ruskoaho H., Vuolteenaho O. Characterization of molecular forms of N-terminal B-type natriuretic peptide in vitro. Clin. Chem. 2010, 56:1822-1829.
81. Palmer S.C., Yandle T.G., Nicholls M.G., Frampton C.M., Richards A.M. Regional clearance of amino-terminal pro-brain natriuretic peptide from human plasma. Eur. J. Heart Fail. 2009, 11:832-839.
82. Pemberton C.J., Johnson M.L., Yandle T.G., Espiner E.A. Deconvolution analysis of cardiac natriuretic peptides during acute volume overload. Hypertension 2000, 36:355-359.
83. Januzzi J.L., Camargo C.A., Anwaruddin S., et al. The N-terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. Am. J. Cardiol. 2005, 95:948-954.
84. Ala-Kopsala M., Magga J., Peuhkurinen K., et al. Molecular heterogeneity has a major impact on the measurement of circulating N-terminal fragments of A- and B-type natriuretic peptides. Clin. Chem. 2004, 50:1576-1588.
85. Foo J.Y., Wan Y., Schulz B.L., et al. Circulating fragments of N-terminal pro-B-type natriuretic peptides in plasma of heart failure patients. Clin. Chem. 2013, 59:1523-1531.
86. Schellenberger U., O'Rear J., Guzzetta A., Jue R.A., Protter A.A., Pollitt N.S. The precursor to B-type natriuretic peptide is an O-linked glycoprotein. Arch. Biochem. Biophys. 2006, 451:160-166.
87. Seferian K.R., Tamm N.N., Semenov A.G., et al. Immunodetection of glycosylated NT-proBNP circulating in human blood. Clin. Chem. 2008, 54:866-873.
88. Semenov A.G., Postnikov A.B., Tamm N.N., et al. Processing of pro-brain natriuretic peptide is suppressed by O-glycosylation in the region close to the cleavage site. Clin. Chem. 2009, 55:489-498.
89. Nishikimi T., Ikeda M., Takeda Y., et al. The effect of glycosylation on plasma N-terminal proBNP-76 levels in patients with heart or renal failure. Heart 2012, 98:152-161.
90. Seferian K.R., Tamm N.N., Semenov A.G., et al. The brain natriuretic peptide (BNP) precursor is the major immunoreactive form of BNP in patients with heart failure. Clin. Chem. 2007, 53:866-873.
91. Nishikimi T., Okamoto H., Nakamura M., et al. Direct immunochemiluminescent assay for proBNP and total BNP in human plasma proBNP and total BNP levels in normal and heart failure. PLoS One 2013, 8:e53233.
92. Dickey D.M., Potter L.R. ProBNP(1-108) is resistant to degradation and activates guanylyl cyclase-A with reduced potency. Clin. Chem. 2011, 57:1272-1278.
93. Ichiki T., Huntley B.K., Heublein D.M., et al. Corin is present in the normal human heart, kidney, and blood, with pro-B-type natriuretic peptide processing in the circulation. Clin. Chem. 2011, 57:40-47.
94. Semenov A.G., Seferian K.R., Tamm N.N., et al. Human pro-B-type natriuretic peptide is processed in the circulation in a rat model. Clin. Chem. 2011, 57:883-890.
95. Moss N.G., Fellner R.C., Qian X., et al. Uroguanylin, an intestinal natriuretic peptide, is delivered to the kidney as an unprocessed propeptide. Endocrinology 2008, 149:4486-4498.
96. Qian X., Moss N.G., Fellner R.C., Goy M.F. Circulating prouroguanylin is processed to its active natriuretic form exclusively within the renal tubules. Endocrinology 2008, 149:4499-4509.
97. Pemberton C.J. Signal peptides: new markers in cardiovascular disease?. Biomark. Med 2014, 8:1013-1019.
98. Siriwardena M., Kleffmann T., Ruygrok P., et al. B-type natriuretic peptide signal peptide circulates in human blood: evaluation as a potential biomarker of cardiac ischemia. Circulation 2010, 122:255-264.